+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 15 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the efficacy and safety of elecoglipron for weight management in adults living with obesity or overweight. This Phase III global study includes two independent, randomized, double-blind, placebo-controlled pivotal studies. Study 1 involves adults without type 2 diabetes mellitus T2DM, while Study 2 includes adults with T2DM. Participants have obesity or overweight with at least one weight-related comorbidity such as hypertension, prediabetes, dyslipidemia, cardiovascular disease, or obstructive sleep apnea. Participants will be randomly assigned to receive one of two doses of elecoglipron or a placebo once daily as oral tablets. The treatment lasts 72 weeks, and the study is conducted in multiple centers worldwide. The primary measure is the percentage change in body weight from baseline at 72 weeks. Secondary measures include absolute weight loss, achievement of specific weight loss percentages, waist circumference reduction, glycemic control, and systolic blood pressure reduction. Throughout the study, participants will undergo regular assessments including body weight and waist measurements, laboratory tests related to glycemic control, and blood pressure monitoring. Researchers will also track the achievement of normoglycemia and glycemic control in participants with elevated HbA1c levels. Safety and efficacy data will be collected until the study completion in 2029, with participants monitored closely during the 72-week treatment period.

Age: 18Years +All GendersPhase 3
325 locations
E

Actively Recruiting

Researchers are evaluating UBT251, a new medication, in adults with type 2 diabetes to determine its effectiveness and safety. The study compares UBT251 to a placebo and also includes a comparison to semaglutide, an existing treatment for type 2 diabetes. The trial is designed as a phase 2 study to find the appropriate dose and assess treatment impact on blood sugar control. Participants will be randomly assigned to one of four groups receiving UBT251, UBT251 placebo, semaglutide, or semaglutide placebo. Each participant will receive their assigned treatment once weekly by subcutaneous injection. The study includes a treatment period lasting up to 40 weeks, with evaluations at various points including weeks 16, 28, and 40. Throughout the study, participants will undergo regular assessments such as measuring glycated hemoglobin HbA1c to track blood sugar levels, body weight, insulin resistance, blood pressure, cholesterol, and kidney function. Safety will be monitored by recording treatment-emergent adverse events up to 46 weeks. The total participation time covers baseline, treatment, and follow-up visits to evaluate the study outcomes comprehensively.

Age: 18Years - 75YearsAll GendersPhase 2
70 locations
R

Actively Recruiting

Researchers are evaluating the safety, tolerability, pharmacokinetics, and early effectiveness of inhaled KIT2014 in patients with moderate to severe Chronic Obstructive Pulmonary Disease COPD. This multicenter, randomized, double-blind, placebo-controlled study includes a dose-ranging design with three ascending dose cohorts. It aims to better understand how KIT2014 behaves in the body and its potential effects over a short treatment period. Participants will receive inhaled KIT2014 or a placebo using a nebulizer. The treatment lasts for 7 days across three different dose levels in sequential cohorts. The study compares KIT2014 with placebo to assess safety and early responses to the drug within this timeframe. During the study, participants will be closely monitored for treatment-emergent adverse events and serious adverse events from the first dose through a follow-up visit on Day 9. Researchers will assess lung function and COPD symptoms according to established guidelines. The total participation period covers screening, 7 days of treatment, and monitoring through the follow-up visit to evaluate safety and tolerability.

Age: 40Years - 80YearsAll GendersPhase 1Phase 2
3 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of AZD6234 in adults who have obesity or are overweight with at least one weight-related health condition but do not have type 2 diabetes. This Phase III study is randomized, double-blind, and conducted across multiple centers worldwide. Participants will be assigned to receive either AZD6234 or a placebo to compare changes in body weight over 68 weeks of treatment. The study treatments involve subcutaneous injections once a week. Participants will receive one of two doses of AZD6234 or a matching placebo. The trial aims to assess how these treatments affect body weight, waist circumference, triglycerides, blood pressure, and fat mass, including measurements by DXA scans in a subset of participants. The treatment period lasts 68 weeks. During the study, participants will have regular visits for assessments including body weight, waist circumference, blood pressure, and blood tests. Some will have DXA scans to measure fat mass. Researchers will monitor safety and track the percentage change in body weight from the start of treatment. The total participation duration includes 68 weeks of treatment with monitoring at specified intervals.

Age: 18Years +All GendersPhase 3
220 locations
E

Actively Recruiting

The trial investigates how well AZD6234 works and its safety in adults who have Type 2 Diabetes Mellitus along with obesity or excess weight. This Phase III, global, randomized, double-blind study compares AZD6234 to a placebo to measure changes in body weight over 68 weeks of treatment. The study aims to better understand weight loss effects and related health changes in this population. Participants will be randomly assigned to one of three groups two different doses of AZD6234 or a placebo. The treatments are given by weekly subcutaneous injections. The study will last 68 weeks, during which participants receive their assigned injections and are monitored regularly for effectiveness and safety. Throughout the study, participants will attend multiple visits for evaluations, including body weight, waist circumference, blood pressure, and lab tests such as haemoglobin A1C and triglycerides. Some may undergo DXA scans to measure fat mass. Researchers will track changes from baseline to assess weight loss and metabolic effects. Safety and tolerability will also be monitored over the treatment period, which lasts about 68 weeks.

Age: 18Years +All GendersPhase 3
230 locations
P

Actively Recruiting

Healthy Volunteer

Researchers are evaluating a new combination treatment using GI-102 and GIB-7 to target key aging-related issues such as immune system aging, metabolic problems, and gut-brain-muscle interactions. This Phase 2a study focuses on healthy adults and cancer survivors to explore whether this dual approach can support healthier aging by addressing inflammation and bodily system balance. GI-102 is an intravenous protein drug given once every four weeks, designed to reactivate the immune system and reduce inflammation associated with aging. GIB-7 is an oral synbiotic containing probiotic strains that support gut health, circadian rhythms, and muscle and cognitive function. Participants receive either the combination of GI-102 and GIB-7 or a placebo over an 8-week period in a randomized, single-blinded setup. Participants will undergo assessments of immune response, muscle function, sleep quality, and quality of life from the start through 10 weeks. Researchers will monitor safety by tracking adverse events and laboratory data. This study lasts about 10 weeks, including treatment and follow-up visits, to evaluate changes in immune cells and physical performance measures.

Age: 18Years - 80YearsAll GendersPhase 2
2 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are studying the safety, tolerability, and how the body processes TESP-0401 in healthy adult volunteers. This randomized, placebo-controlled study aims to understand these factors after both single and multiple intravenous doses of the drug. The study is designed as a Phase 1 trial to carefully assess how TESP-0401 behaves in the body and to monitor any adverse effects in healthy participants. Participants will receive TESP-0401 or a placebo through intravenous infusion over 60 minutes while fasting. The study includes two parts Part A with single ascending doses and Part B with multiple ascending doses administered once daily for seven days. Each participant will be assigned randomly to either the experimental or placebo group in a parallel design. During the study, participants will be closely monitored for safety through clinical lab tests, vital signs, ECG readings, and physical exams up to eight days after the last dose. Researchers will measure drug concentrations, how quickly it reaches peak levels, clearance rates, half-life, volume of distribution, and drug accumulation over up to nine days. The entire participation includes confinement at the clinical research unit and adherence to study restrictions to ensure accurate monitoring of safety and pharmacokinetics.

Age: 18Years - 65YearsAll GendersPhase 1
1 location
P

Actively Recruiting

Researchers are evaluating Ratutrelvir 83-0060, a drug that inhibits the main protease of SARS-CoV-2, along with Paxlovid Nirmatrelvir plus Ritonavir, to understand their safety and effectiveness in adults with mild to moderate COVID-19 who are not hospitalized. This open-label, randomized Phase 2a study aims to determine a safe and effective dose of Ratutrelvir and compare it with standard care, providing important information on how these treatments may help manage COVID-19 symptoms and recovery. Participants will be assigned to receive either Ratutrelvir or Paxlovid alongside standard care. The study is multicenter and open-label, meaning both researchers and participants know which treatment is given. The trial includes an experimental group receiving Ratutrelvir, a comparator group receiving Paxlovid, and a non-randomized group receiving Ratutrelvir. Treatment is given during the study period, and the research team monitors the drugs concentration in the blood to understand how it behaves in the body. During the 28-day study period, participants will be closely monitored for safety based on the occurrence and severity of any adverse events. The team will assess how long it takes for COVID-19 symptoms to improve and recover fully. Blood samples will be collected up to day 11 to analyze drug levels. Participants will undergo symptom evaluations regularly, and their health will be tracked throughout the study to ensure safety and gather data on treatment effects.

Age: 18Years +All GendersPhase 2
15 locations
L

Actively Recruiting

Researchers are investigating maridebart cafraglutide for people with obesity or overweight to evaluate its long-term effects on weight management, safety, and tolerability. This trial is an extension of a previous study trial 20210181 and aims to provide more information about how the drug works over an extended period. It is a phase 3, randomized, double-blind study sponsored by Amgen. Participants will receive different doses of maridebart cafraglutide or placebo depending on their treatment in the previous trial. Some will continue with low dose every 4 weeks, others will be re-randomized to receive medium or high doses on schedules of every 4, 8, or 12 weeks, or placebo injections every 4 weeks. Participants who had placebo before will undergo a dose-escalation phase before starting the high dose treatment. During the study, participants will be monitored for changes in body weight, waist circumference, quality of life, and any side effects or adverse events over about 48 weeks of treatment. The trial will assess how well weight loss is maintained and record any treatment-emergent adverse events up to 60 weeks. Participants will have regular visits for injections and safety assessments throughout the study period.

Age: 18Years - 99YearsAll GendersPhase 3
92 locations
E

Actively Recruiting

Researchers are evaluating a new way to deliver treatment using the ECAP-controlled closed-loop spinal cord stimulation SCS system called the Evoke System. This study focuses on patients who experience chronic pain in the trunk andor limbs. The goal is to test and assess new software and hardware features that may improve how the Evoke System delivers treatment. Participants will use the Evoke Spinal Cord Stimulation System, which measures electrical activity called evoked compound action potentials ECAPs. The device automatically adjusts the stimulation current to keep the ECAP amplitude consistent. This study involves a single group of participants using this novel device and will continue through to study completion, which may last up to two years. During the study, participants will be monitored for changes in ECAPs measured by the Evoke System. Researchers will evaluate these changes over the course of the study to understand how the device functions with the new features. Participants will need to provide informed consent and comply with study requirements while using the device. The total participation time can last up to two years, with regular assessments conducted throughout this period.

Age: 18Years +All GendersPhase Not Applicable
25 locations

1-10 of 15

1